Clinical trial
Phase II Study Using Thalidomide for the Treatment of ALS
NCT00140452 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00140452 |
|---|---|
| Title | Phase II Study Using Thalidomide for the Treatment of ALS |
| Official title | Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis, ALS |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 24 |
| Start date | Feb 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Sep 1, 2005 |
| Last update posted | Nov 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: